Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock, $0.01 par value
-
Shares outstanding
-
82,051,282
-
Total 13F shares
-
497,189
-
Share change
-
+8,553
-
Total reported value
-
$15,472,823
-
Price per share
-
$31.12
-
Number of holders
-
11
-
Value change
-
+$265,904
-
Number of buys
-
5
-
Number of sells
-
4
Institutional Holders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) as of Q4 2025
As of 31 Dec 2025,
Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) was held by
11 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
497,189 shares.
The largest 10 holders included
Kopp Family Office, LLC, Hennion & Walsh Asset Management, Inc., J. Safra Sarasin Holding AG, SG Americas Securities, LLC, StoneCrest Wealth Management, Inc., DIVERSIFIED TRUST CO, NISA INVESTMENT ADVISORS, LLC, GAMMA Investing LLC, EASTERN BANK, and Versant Capital Management, Inc.
This page lists
11
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.